WFRF:(Berglund Åke)
Search: WFRF:(Berglund Åke) > (2015-2019) > First-in-human, pha...
- 3 of 14
- Previous record
- Next record
- To hitlist
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
-
- Berglund, Åke (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Ullen, Anders (author)
- Karolinska Institutet
-
- Lisyanskaya, Alla (author)
- City Clin Oncol Ctr, St Petersburg State Healthcare Inst, St Petersburg, Russia.
- show more...
- show less...
- (creator_code:org_t)
- 2015-11-10
- 2015
- English.
- In: Investigational new drugs. - : Springer Science and Business Media LLC. - 0167-6997 .- 1573-0646. ; 33:6, s. 1232-1241
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Purpose Melflufen (melphalan flufenamide, previously designated J1) is an optimized and targeted derivative of melphalan, hydrolyzed by aminopeptidases overexpressed in tumor cells resulting in selective release and trapping of melphalan, and enhanced activity in preclinical models. Methods This was a prospective, single-armed, open-label, first-in-human, dose-finding phase I/IIa study in 45 adult patients with advanced and progressive solid tumors without standard treatment options. Most common tumor types were ovarian carcinoma (n = 20) and non-small-cell lung cancer (NSCLC, n = 11). Results In the dose-escalating phase I part of the study, seven patients were treated with increasing fixed doses of melflufen (25-130 mg) Q3W. In the subsequent phase IIa part, 38 patients received in total 115 cycles of therapy at doses of 30-75 mg. No dose-limiting toxicities (DLTs) were observed at 25 and 50 mg; at higher doses DLTs were reversible neutropenias and thrombocytopenias, particularly evident in heavily pretreated patients, and the recommended phase II dose (RPTD) was set to 50 mg. Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients. One NSCLC patient received nine cycles of melflufen and progressed after 7 months of therapy. Conclusions In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. Reversible and manageable bone marrow suppression was identified as a DLT. Clinical activity is suggested in ovarian cancer, but modest activity in treatment of refractory NSCLC.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- Melphalan flufenamide
- Melflufen
- J1
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Investigational new drugs (Search for host publication in LIBRIS)
To the university's database
- 3 of 14
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Berglund, Åke
- Ullen, Anders
- Lisyanskaya, All ...
- Orlov, Sergey
- Hagberg, Hans
- Tholander, Bengt
- show more...
- Lewensohn, Rolf
- Nygren, Peter
- Spira, Jack
- Harmenberg, Joha ...
- Jerling, Markus
- Alvfors, Carina
- Ringbom, Magnus
- Nordstrom, Eva
- Soderlind, Karin
- Gullbo, Joachim
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Basic Medicine
- and Pharmacology and ...
- Articles in the publication
- Investigational ...
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
